Compare Cassava Sciences Inc (FLNA) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs H2O America — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while H2O America trades at $64.15 (market cap $2.62B). The key difference: H2O America is far larger — about 49.3× Cassava Sciences Inc's market cap, and H2O America pays a 2.81% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HTO | |
|---|---|---|
Market Cap | $53.14M | $2.62B |
Sector | Health | Technology |
52-Week High | $4.64 | $62.94 |
52-Week Low | $1.09 | $44.44 |
Enterprise Value | -$33.43M | $4.34B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
HTO trades at $63.94, up 1.59% with strong technical momentum as moving averages signal bullish sentiment. The stock shows solid fundamentals with 12.87% net income margin and consistent earnings beats in three of the last four quarters. Recent corporate actions include a $0.44 dividend payment scheduled for June 2026, while analyst consensus remains strongly positive with 80% buy ratings.
The outlook remains favorable given HTO's stable utility business model and projected EPS growth. Key risks include high capital expenditure requirements and sensitivity to regulatory rate changes. With the current price near analyst targets, further upside may depend on Q2 2026 earnings exceeding expectations when reported on July 27, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
